Liposomal mitoxantrone plus tislelizumab in patients with relapsed or refractory extranodal natural killer/T-cell lymphoma: a phase 1b/2 trial - PubMed
5 hours ago
- #immunotherapy
- #clinical trial
- #NK/T-cell lymphoma
- Phase 1b/2 trial evaluated liposomal mitoxantrone (Lipo-MIT) plus tislelizumab in relapsed/refractory extranodal NK/T-cell lymphoma (R/R ENKTL).
- No dose-limiting toxicities observed; recommended phase 2 dose of Lipo-MIT was 20 mg/m².
- Complete response rate was 53%, meeting primary efficacy endpoint with median progression-free survival of 8.2 months.
- Common grade ≥3 adverse events included leukopenia (53%), neutropenia (40%), and febrile neutropenia (18%).
- Combination therapy showed promising anti-tumor activity and acceptable safety profile in R/R ENKTL patients.